RISPERIDONE AUGMENTATION OF CLOZAPINE

被引:51
作者
MCCARTHY, RH
TERKELSEN, KG
机构
[1] Cornell University Medical College, New York Hospital, Westchester Division, White Plains, NY 10605
关键词
D O I
10.1055/s-2007-979590
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
While effective as a single agent in a significant proportion of treatment refractory patients, clozapine is often used in combination with other medications, including classical neuroleptics (1), mood stabilizers and antidepressants (2), benzodiazepines (3) and lithium (4). In Denmark, where clozapine has been in near continuous use since 1975, up to 60 % of clozapine patients receive additional medication (4). Classical neuroleptics, often at antipsychotic levels, are the medications most frequently added, and are used in 30-35 % of patients receiving clozapine (4, 5). Clozapine, due to its low D-2-blocking effect, may be therapeutically insufficient to contain symptoms and additional agents may be required (4). In controlled clinical trials risperidone has been shown to be superior to haloperidol (6), but has not yet been rigorously compared to clozapine. In light of its established efficacy and pharmacological profile (7) risperidone may be reasonably construed to be a medication with efficacy somewhere between clozapine and classical neuroleptics. As such, it may be especially well suited for use with clozapine as a part of an augmentation strategy. There are no reports in the literature describing the concurrent use of risperidone and clozapine. We present two cases demonstrating augmentation of clozapine's effects through combined use with clozapine.
引用
收藏
页码:61 / 63
页数:3
相关论文
共 12 条
  • [1] ALVIR JMJ, 1993, NEW ENGL J MED, V135, P162
  • [2] CENTORRINO F, 1994, J CLIN PSYCHOPHARM, V14, P119
  • [3] CHOUINARD G, 1993, J CLIN PSYCHOPHARM, V13, P25
  • [4] DYSTONIC REACTION AND RELAPSE WITH CLOZAPINE DISCONTINUATION AND RESPERIDONE INITIATION
    DICKSON, R
    WILLIAMS, R
    DALBY, JT
    [J]. CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE, 1994, 39 (03): : 184 - 184
  • [5] FITTON A, 1990, DRUGS, V40, P722
  • [6] CLOZAPINE AND BIPOLAR DISORDER
    FRANKENBURG, FR
    [J]. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 1993, 13 (04) : 289 - 290
  • [7] JANSSEN PAJ, 1988, J PHARMACOL EXP THER, V244, P685
  • [8] LEPPIG M, 1989, PSYCHOPHARMACOLOGY S, V99, P118
  • [9] MCCARTHY RH, 1994, J CLIN PSYCHOPHARM, V14, P281
  • [10] NABER D, 1992, BRIT J PSYCHIATRY S, V54, P54